Incidence, prevalence, and trend analysis of the use of insulin delivery systems in the United States (2005 to 2011)

Current Medical Research and Opinion

Volumn 31, Issue 5, 2015, Pages 891-899

  Perez Nieves, Magaly ^a   Jiang, Dingfeng ^a   Eby, Elizabeth ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Diabetes mellitus; Incidence; Insulin delivery systems; Insulins; Prevalence

Indexed keywords

INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; RECOMBINANT HUMAN INSULIN; ANTIDIABETIC AGENT;

ADULT; BILLING AND CLAIMS; CONFERENCE PAPER; DIABETIC PATIENT; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INJECTION PEN; INSULIN SYRINGE; INSULIN TREATMENT; INSULIN VIAL; MAJOR CLINICAL STUDY; MALE; MEDICARE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACY; PREVALENCE; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; UNITED STATES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FACTUAL DATABASE; SYRINGE;

DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; SYRINGES; UNITED STATES;

EID: 84928177288     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1020366     Document Type: Conference Paper

References (38)

1. International Diabetes Federation (IDF). Diabetes Atlas. Brussels, Belgium: IDF, 2013. Available at: http://www.idf.org/sites/default/files/DA6 Regional-factsheets-0.pdf [Last accessed 28 February 2013]
2. American Diabetes Association (ADA). Living with Diabetes, Insulin Routines. Alexandria, VA: ADA, 2013. Available at: http://www.diabetes.org/living-withdiabetes/ treatment-and-care/medication/insulin/insulin-routines.html [Last accessed 28 February 2013]
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
4. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-9
5. Martin CL, Albers J, Herman WH, et al.; DCCT/EDIC Research Group. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006;29:340-4
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
7. Molife C, Lee LJ, Shi L, et al. Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe. Diabetes Technol Ther 2009;11:529-38
8. Ahmann A, Szeinbach SL, Gill J, et al. Comparing patient preferences and healthcare provider recommendations with the pen versus vial-and-syringe insulin delivery in patients with type 2 diabetes. Diabetes Technol Ther 2014;16:76-83
9. Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther 2004;26:1498-505
10. Eby EL, Boye KS, Lage MJ. Mealtime insulin administration: pens versus vials. Am J Pharm Benefits 2013;5:e159-67
11. Davis SN, Wei W, Garg S. Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting. Endocr Pract 2011;17:845-52
12. Xie L, Zhou S, Wei W, et al. Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus. Diabetes Technol Ther 2013;15:230-6
13. Lee LJ, Li Q, Reynolds MW, Engelman W. Trend analyses of insulin delivery systems in the United States. J Diabetes Sci Technol 2011;5:1116-23
14. Levemir [package insert]. Plainsboro, NJ: Novo Nordisk, 2013
15. Lantus [package insert]. Bridgewater, NJ: Sanofi-Aventis US LLC, 2013
16. Patient Information for Novolin N. RxList Inc., 2009. Available at: http:// www.rxlist.com/novolin-n-innolet-drug/medication-guide.htm [Last accessed 13 October 2014]
17. Humulin N [package insert]. Indianapolis, IN: Eli Lilly and Company, 2013
18. Humalog [package insert]. Indianapolis, IN: Eli Lilly and Company, 2013
19. NovoLog [package insert]. Plainsboro, NJ: Novo Nordisk, 2013
20. Apidra [package insert]. Bridgewater, NJ: Sanofi-Aventis US LLC, 2014
21. Novolin R [package insert]. Plainsboro, NJ: Novo Nordisk, 2013
22. Humulin R [package insert]. Indianapolis, IN: Eli Lilly and Company, 2013
23. Humalog Mix75/25 [package insert]. Indianapolis, IN: Eli Lilly and Company, 2013
24. Humalog Mix50/50 [package insert]. Indianapolis, IN: Eli Lilly and Company, 2013
25. NovoLog Mix 70/30 [package insert]. Plainsboro, NJ: Novo Nordisk, 2013
26. Humulin 70/30 [package insert]. Indianapolis, IN: Eli Lilly and Company, 2013
27. Novolin 70/30 [prescribing information]. Plainsboro, NJ: Novo Nordisk, 2013
28. Rubin RR, Peyrot M. Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care 2008;31:430-2
29. Shaghouli AA, Shah BR. The prescription of insulin pen devices versus syringes for older people with diabetes. Diabetes Technol Ther 2009;11:439-42
30. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
31. Baser O, Bouchard J, DeLuzio T, et al. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe. Adv Ther 2010;27:94-104
32. Cobden D, Lee WC, Balu S, et al. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy 2007;27:948-62
33. Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28:1710-25
34. Pawaskar MD, Camacho FT, Anderson RT, et al. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther 2007;29(6 Pt 1):1294-305
35. Jeitler K, Horvath K, Berghold A, et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 2008;51:941-51
36. Leinung MC, Thompson S, Luo M, et al. Use of insulin pump therapy in patients with type 2 diabetes after failure with multiple daily injections. Endocr Pract 2013;19:9-13
37. Wolff-McDonagh P, Kaufmann J, Foreman S, et al. Using insulin pump therapy in poorly controlled type 2 diabetes. Diabetes Educ 2010;36:657-65
38. Gentry CK, Cross LB, Gross BN, et al. Retrospective analysis and patient satisfaction assessment of insulin pump therapy in patients with type 2 diabetes. South Med J 2011;104:24-8